To further investigate whether I3A increased MHC‐I expression via JAK2‐STAT3 signaling axis, we used Ruxolinitib, a JAK1/2 inhibitor, to treat tumor cells together with I3A. This evidence concerns the gene STAT3 and neoplasm.